Send us Feedback

Sanofi-Aventis SA (SNY)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

SNY » Topics » Net Income Attributable to Equity Holders of the Company

This excerpt taken from the SNY 20-F filed Mar 4, 2009.

Net Income Attributable to Equity Holders of the Company

 

Net income attributable to equity holders of the Company for 2007 was €5,263 million, against €4,006 million for 2006.

 

The table below shows trends in net income attributable to equity holders of the Company by business segment for 2007 and 2006:

 

(€ million)

    2007    2006

Pharmaceuticals

    4,851    3,649

Vaccines

    412    357
         

Total net income attributable to equity holders of the Company

    5,263    4,006
         

 

Earnings per share (EPS) was €3.91, compared with €2.97 for 2006, based on an average number of shares outstanding of 1,346.9 million in 2007 (2006: 1,346.8 million).

 

This excerpt taken from the SNY 20-F filed Mar 7, 2008.

Net Income Attributable to Equity Holders of the Company

 

Net income attributable to equity holders of the Company totaled €4,006 million, versus €2,258 million in 2005.

 

The table below shows trends in net income attributable to equity holders of the Company by business segment for 2005 and 2006:

 

(€ million)

    2006    2005

Pharmaceuticals

    3,649    2,207

Vaccines

    357    51
         

Total net income attributable to equity holders of the Company

    4,006    2,258
         

 

101

Table of Contents
This excerpt taken from the SNY 6-K filed Aug 2, 2007.

3.1.19 Net income attributable to equity holders of the Company

Net income attributable to equity holders of the Company was €2,665 million in the first half of 2007, compared with €2,381 million in the first half of 2006.

Earnings per share was €1.97, against €1.77 for the first half of 2006, based on an average number of shares outstanding of 1,351.5 million for the first half of 2007 and 1,345.2 million for the first half of 2006.

The table below shows net income attributable to equity holders of the Company for the six months ended June 30, 2007 and June 30, 2006, split by business segment:

 

(€ million)

   

June 30,

2007

   

June 30,

2006

Pharmaceuticals

    2,567    2,282

Human Vaccines

         98         99

Total net income attributable to equity holders of the Company

    2,665    2,381

 

18

3.2  Adjusted net income (1)

 

3.2.1

Reconciliation of net income attributable to equity holders of the Company to adjusted net income (1)

 

  (€ million)

   

6 months to  

June 30, 2007  

   

6 months to  

June 30, 2006  

  Net income attributable to equity holders of the Company

    2,665        2,381    

  Material accounting adjustments related to business combinations:

    1,130        1,530    

  n     elimination of expense arising from workdown of acquired inventories remeasured at fair value, net of tax

    -        6    

  n     elimination of amortization and impairment of intangible assets, net of tax (portion attributable to equity holders of the Company)

    1,112        1,460    

  n     elimination of charges arising from the impact of acquisitions on associates (workdown of acquired inventories, amortization and impairment of intangible assets, and impairment of goodwill)

    18*        64*    

  n     elimination of impairment of goodwill

    -        -    

  Elimination of acquisition-related integration and restructuring costs, net of tax

    -        53    

  Adjusted net income (1)

    3,795        3,964    

  Adjusted earnings per share (1) (in euros)

    2.81        2.95    

 

  *

Impact of the Zentiva acquisition: €3 million in the first half of 2007, €7 million in the first half of 2006.

This excerpt taken from the SNY 20-F filed Apr 3, 2007.

Net Income Attributable to Equity Holders of the Company

 

Consolidated net income attributable to equity holders of the Company amounted to €2,258 million in 2005, compared to pro forma €2,316 million for 2004. The impact of the workdown of Aventis inventory remeasured at fair value on this line was an additional charge of €270 million in 2005. Earnings per share was €1.69, compared to pro forma €1.74 for 2004, based on a total number of shares of 1,336.5 million in 2005 and 1,333.4 million in 2004.

 

This excerpt taken from the SNY 6-K filed Aug 3, 2006.

3.1.19. Net income attributable to equity holders of the company

Net income attributable to equity holders of the company for the six months to June 30, 2006 was €2,381 million, against €1,087 million for the comparable period of 2005.

Earnings per share was €1.77, against €0.81 for the first half of 2005, based on an average number of shares outstanding of 1,345.2 million in the first half of 2006 and 1,335.1 million in the first half of 2005.

The table below shows comparatives for net income attributable to equity holders of the company by business segment for the six months to June 30, 2006 and June 30, 2005:

 

(€ million)

    H1 2006          H1 2005  

Pharmaceuticals

    2,282       1,188  

Vaccines

    99         (101 )

Total net income attributable to equity holders of the company

    2,381         1,087  

EXCERPTS ON THIS PAGE:

20-F
Mar 4, 2009
20-F
Mar 7, 2008
6-K
Aug 2, 2007
20-F
Apr 3, 2007
6-K
Aug 3, 2006

RELATED TOPICS for SNY:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki